Recruiting studies: Refractory Head And Neck Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malign
Phase 1/Phase 2 · 13 location(s) · GV20 Therapeutics · NCT05669430 A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Phase 1 · 9 location(s) · Normunity AccelCo, Inc. · NCT07182149 A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metas
Phase 1/Phase 2 · 3 location(s) · Taipei Veterans General Hospital, Taiwan · NCT07136545 Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994 A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05859074 RAPA-201 Therapy of Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Rapa Therapeutics LLC · NCT05144698 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801 Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spre
Phase 3 · 192 location(s) · National Cancer Institute (NCI) · NCT06589804 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Radiopharm Theranostics, Ltd · NCT07189871 A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Phase 1 · 1 location(s) · West China Hospital · NCT07106827 Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06096038 A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Phase 1 · 6 location(s) · Sutro Biopharma, Inc. · NCT07227168 Study of GV20-0251 in Participants With Solid Tumor Malignancies
Phase 1/Phase 2 · 3 location(s) · GV20 Therapeutics · NCT07070518 A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187 Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07584499 Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Re
Phase 1 · 2 location(s) · University of California, Davis · NCT06211335 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024 Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
Phase 2 · 1 location(s) · Fudan University · NCT07403136 TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 · 41 location(s) · Tizona Therapeutics, Inc · NCT04485013

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.